Day One Biopharmaceuticals (DAWN) to Release Earnings on Tuesday

Day One Biopharmaceuticals (NASDAQ:DAWN) is expected to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Day One Biopharmaceuticals Stock Down 2.4%

Shares of DAWN opened at $11.78 on Friday. The business has a fifty day moving average of $10.48 and a 200 day moving average of $8.64. The company has a market cap of $1.21 billion, a PE ratio of -7.75 and a beta of -1.26. Day One Biopharmaceuticals has a 52-week low of $5.64 and a 52-week high of $13.20.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Lauren Merendino sold 5,814 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $67,442.40. Following the transaction, the insider directly owned 60,157 shares in the company, valued at $697,821.20. This trade represents a 8.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Charles N. York II sold 6,065 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $70,354.00. Following the completion of the sale, the chief financial officer owned 312,025 shares of the company’s stock, valued at $3,619,490. This represents a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 36,461 shares of company stock worth $422,948 over the last three months. Corporate insiders own 6.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Quarry LP bought a new position in shares of Day One Biopharmaceuticals during the third quarter valued at approximately $49,000. Prudential Financial Inc. purchased a new stake in Day One Biopharmaceuticals during the second quarter worth $69,000. Lazard Asset Management LLC bought a new stake in Day One Biopharmaceuticals during the 2nd quarter valued at $89,000. LPL Financial LLC purchased a new position in shares of Day One Biopharmaceuticals in the 4th quarter valued at $102,000. Finally, Virtus Advisers LLC bought a new position in shares of Day One Biopharmaceuticals in the 4th quarter worth $104,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on DAWN shares. JPMorgan Chase & Co. increased their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Zacks Research raised shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Monday, December 29th. Finally, Piper Sandler increased their price target on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $25.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.